US Stock MarketDetailed Quotes
BPMC Blueprint Medicines
- 95.100
- +0.470+0.50%
Close Nov 27 16:00 ET
- 95.100
- 0.0000.00%
Post 16:02 ET
6.04BMarket Cap-45502P/E (TTM)
95.540High92.530Low813.53KVolume95.250Open94.630Pre Close76.53MTurnover1.30%Turnover RatioLossP/E (Static)63.53MShares121.90052wk High19.29P/B5.98BFloat Cap70.39052wk Low--Dividend TTM62.84MShs Float125.610Historical High--Div YieldTTM3.18%Amplitude13.040Historical Low94.072Avg Price1Lot Size
Blueprint Medicines Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 126.61%128.18M | 139.98%138.16M | 51.87%96.12M | 22.22%249.38M | 85.55%71.96M | -14.26%56.57M | 57.52%57.57M | 0.89%63.29M | 13.30%204.04M | -63.76%38.78M |
| Operating revenue | 126.61%128.18M | 139.98%138.16M | 51.87%96.12M | 22.22%249.38M | 85.55%71.96M | -14.26%56.57M | 57.52%57.57M | 0.89%63.29M | 13.30%204.04M | -63.76%38.78M |
| Cost of revenue | -30.55%1.93M | 226.86%7.59M | 0.50%3.19M | -52.06%8.54M | -94.64%260K | -7.27%2.78M | -52.46%2.32M | -37.49%3.18M | -0.67%17.81M | -35.78%4.85M |
| Gross profit | 134.74%126.25M | 136.33%130.56M | 54.59%92.93M | 29.33%240.84M | 111.29%71.7M | -14.60%53.78M | 74.50%55.25M | 4.27%60.11M | 14.85%186.22M | -65.89%33.93M |
| Operating expense | -3.19%175.23M | -4.61%173.61M | -6.16%171.75M | 1.13%722.86M | -2.75%176.85M | -2.48%180.99M | -2.76%181.99M | 14.25%183.02M | -10.24%714.79M | -55.76%181.86M |
| Selling and administrative expenses | 27.12%89.93M | 24.20%89.34M | 17.77%83.56M | 24.34%295.14M | 23.89%79.32M | 22.80%70.74M | 22.57%71.93M | 24.35%70.95M | 21.55%237.37M | 18.12%64.02M |
| -Selling and marketing expense | 104.58%26.74M | 99.77%22.71M | 68.46%16.93M | ---- | ---- | 69.34%13.07M | 18.10%11.37M | --10.05M | ---- | ---- |
| -General and administrative expense | 9.56%63.19M | 10.02%66.63M | 9.40%66.63M | ---- | ---- | 15.60%57.67M | 23.44%60.56M | --60.9M | ---- | ---- |
| Research and development costs | -22.63%85.3M | -23.43%84.27M | -21.31%88.19M | -10.41%427.72M | -17.23%97.54M | -13.85%110.25M | -14.33%110.06M | 8.67%112.07M | -20.57%477.42M | -66.98%117.84M |
| Operating profit | 61.50%-48.97M | 66.04%-43.05M | 35.87%-78.82M | 8.81%-482.02M | 28.91%-105.15M | -3.75%-127.21M | 18.49%-126.75M | -19.87%-122.91M | 16.65%-528.57M | 52.53%-147.93M |
| Net non-operating interest income expense | -100.00%-7.62M | -71.77%-6.86M | -1.31%-5.9M | -12.08%-18.79M | 44.06%-5.17M | 54.65%-3.81M | -1,035.83%-4M | -1,416.52%-5.82M | -802.72%-16.77M | -2,095.68%-9.24M |
| Non-operating interest income | 19.52%11.15M | 28.22%9.94M | 55.56%9.18M | ---- | ---- | 216.24%9.33M | 1,689.61%7.75M | --5.9M | ---- | ---- |
| Non-operating interest expense | 42.85%18.77M | 43.04%16.8M | 28.62%15.07M | ---- | ---- | 15.79%13.14M | 195,650.00%11.75M | --11.72M | ---- | ---- |
| Total other finance cost | ---- | ---- | ---- | 12.08%18.79M | ---- | ---- | ---- | ---- | 802.72%16.77M | ---- |
| Other net income (expense) | 123.49%587K | 100.91%17K | 56,240.00%174.03M | 25.09%-5.2M | -20.09%-532K | -96.93%-2.5M | -22.93%-1.86M | 91.66%-310K | 25.25%-6.94M | 90.98%-443K |
| Earnings from equity interest | --0 | --0 | --0 | 52.44%-4.26M | 102.40%45K | -6.37%-1.77M | 42.47%-1.23M | 60.31%-1.3M | -14.70%-8.95M | 58.69%-1.87M |
| Special income (charges) | --0 | --18K | --173.66M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| -Less:Other special charges | ---- | ---18K | ---173.66M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other non- operating income (expenses) | 180.63%587K | 99.84%-1K | -61.87%376K | -147.21%-946K | -140.38%-577K | -283.84%-728K | -199.05%-626K | 317.66%986K | 234.59%2M | 476.05%1.43M |
| Income before tax | 58.06%-56M | 62.37%-49.89M | 169.22%89.32M | 8.38%-506.02M | 29.66%-110.86M | -0.94%-133.52M | 15.31%-132.6M | -21.95%-129.04M | 13.85%-552.28M | 50.13%-157.61M |
| Income tax | 38.58%273K | -46.32%102K | -65.38%180K | -81.51%968K | -94.11%61K | -77.77%197K | -93.93%190K | 182.61%520K | 74.48%5.24M | -60.65%1.04M |
| Net income | 57.91%-56.28M | 62.35%-49.99M | 168.80%89.14M | 9.06%-506.98M | 30.09%-110.92M | -0.41%-133.71M | 16.85%-132.79M | -22.23%-129.56M | 13.44%-557.52M | 50.22%-158.65M |
| Net income continuous Operations | 57.91%-56.28M | 62.35%-49.99M | 168.80%89.14M | 9.06%-506.98M | 30.09%-110.92M | -0.41%-133.71M | 16.85%-132.79M | -22.23%-129.56M | 13.44%-557.52M | 50.22%-158.65M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 57.91%-56.28M | 62.35%-49.99M | 168.80%89.14M | 9.06%-506.98M | 30.09%-110.92M | -0.41%-133.71M | 16.85%-132.79M | -22.23%-129.56M | 13.44%-557.52M | 50.22%-158.65M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 57.91%-56.28M | 62.35%-49.99M | 168.80%89.14M | 9.06%-506.98M | 30.09%-110.92M | -0.41%-133.71M | 16.85%-132.79M | -22.23%-129.56M | 13.44%-557.52M | 50.22%-158.65M |
| Basic earnings per share | 59.55%-0.89 | 63.47%-0.8 | 167.44%1.45 | 10.48%-8.37 | 31.32%-1.82 | 1.35%-2.2 | 18.28%-2.19 | -20.11%-2.15 | 15.08%-9.35 | 50.93%-2.65 |
| Diluted earnings per share | 59.55%-0.89 | 63.47%-0.8 | 165.12%1.4 | 10.48%-8.37 | 31.32%-1.82 | 1.35%-2.2 | 18.28%-2.19 | -20.11%-2.15 | 15.08%-9.35 | 50.93%-2.65 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
